Large Cell Neuroendocrine Carcinoma
NCI Definition: A usually aggressive carcinoma composed of large malignant cells which display neuroendocrine characteristics. It is characterized by the presence of high mitotic activity and necrotic changes. The vast majority of cases are positive for neuron-specific enolase. Representative examples include lung, breast, cervical, and thymic neuroendocrine carcinomas. 
Large cell neuroendocrine carcinomas most frequently harbor alterations in TP53, STK11, RB1, KRAS, and KEAP1 .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and TP53 Nonsense are the most common alterations in large cell neuroendocrine carcinoma .
There is 1 clinical trial for large cell neuroendocrine carcinoma, of which 0 are open and 1 is completed or closed. Of the trial that contains large cell neuroendocrine carcinoma as an inclusion criterion, 1 is phase 2 (0 open).
Etoposide and pembrolizumab are the most common interventions in large cell neuroendocrine carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.